此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

一项针对 PD-L1 阳性局部复发性不可手术或转移性三阴性乳腺癌患者进行的 Dato-DXd 联合或不联合 Durvalumab 与研究者选择的化疗联合 Pembrolizumab 进行比较的 III 期研究

2026年9月24日 更新者:AstraZeneca

一项 III 期、开放标签、随机研究,比较使用或不使用 Durvalumab 的 Datopotamab Deruxtecan (Dato-DXd) 与研究者选择的化疗(紫杉醇、白蛋白结合型紫杉醇或吉西他滨 + 卡铂)联合派姆单抗治疗 PD-L1 阳性患者的情况局部复发性不可手术或转移性三阴性乳腺癌 (TROPION-Breast05)

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without durvalumab compared with investigator's choice chemotherapy in combination with pembrolizumab in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.

研究概览

详细说明

The primary objective of the study is to demonstrate superiority of Dato-DXd + durvalumab relative to ICC + pembrolizumab by assessment of PFS as assessed by BICR in participants with PD-L1 positive locally recurrent inoperable or metastatic TNBC.

The study will be stratified based on geographic location (US/Canada/Europe vs. Dato-DXd monotherapy enrolling countries vs. rest of world), disease-free interval (DFI) history (de novo vs. prior DFI 6 to 12 months vs. prior DFI > 12 months), and prior PD-1/PD-L1 treatment for early stage TNBC (yes vs. no).

This study aims to see if Dato-DXd with durvalumab allows patients to live longer without their breast cancer getting worse, or simply to live longer, compared to patients receiving standard of care chemotherapy and pembrolizumab. This study is also looking to see how the treatment and the breast cancer affects patients' quality of life.

研究类型

介入性

注册 (估计的)

625

阶段

  • 第三阶段

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

      • Anyang、中国、455000
        • 招聘中
        • Research Site
      • Beijing、中国、100044
        • 招聘中
        • Research Site
      • Beijing、中国、100142
        • 招聘中
        • Research Site
      • Bengbu、中国、233004
        • 招聘中
        • Research Site
      • Changchun、中国、130021
        • 招聘中
        • Research Site
      • Changsha、中国、410008
        • 招聘中
        • Research Site
      • Changsha、中国、410013
        • 招聘中
        • Research Site
      • Chengdu、中国、610000
        • 招聘中
        • Research Site
      • Chengdu、中国、610041
        • 招聘中
        • Research Site
      • Chongqing、中国、400030
        • 撤销
        • Research Site
      • Fuzhou、中国、350014
        • 招聘中
        • Research Site
      • Guangzhou、中国、510120
        • 招聘中
        • Research Site
      • Guangzhou、中国、510060
        • 招聘中
        • Research Site
      • Guangzhou、中国、510700
        • 招聘中
        • Research Site
      • Hangzhou、中国、310009
        • 招聘中
        • Research Site
      • Hangzhou、中国、310022
        • 招聘中
        • Research Site
      • Hangzhou、中国、310016
        • 招聘中
        • Research Site
      • Harbin、中国、150081
        • 招聘中
        • Research Site
      • Hefei、中国、230031
        • 招聘中
        • Research Site
      • Jinan、中国、250021
        • 主动,不招人
        • Research Site
      • Meizhou、中国、514031
        • 招聘中
        • Research Site
      • Nanchang、中国、330009
        • 招聘中
        • Research Site
      • Nanjing、中国、210009
        • 招聘中
        • Research Site
      • Nanjing、中国、2100008
        • 招聘中
        • Research Site
      • Nanning、中国、530021
        • 招聘中
        • Research Site
      • Shandong、中国
        • 招聘中
        • Research Site
      • Shanghai、中国、200025
        • 招聘中
        • Research Site
      • Shanghai、中国、200080
        • 完全的
        • Research Site
      • Shenyang、中国、110004
        • 招聘中
        • Research Site
      • Taiyuan、中国、030000
        • 招聘中
        • Research Site
      • Tianjin、中国、300000
        • 招聘中
        • Research Site
      • Wenzhou、中国、325000
        • 招聘中
        • Research Site
      • Wuhan、中国、430022
        • 招聘中
        • Research Site
      • Wuhan、中国、430079
        • 招聘中
        • Research Site
      • Xi'an、中国、710061
        • 招聘中
        • Research Site
      • Xiamen、中国、361003
        • 招聘中
        • Research Site
      • Xintai、中国、54031
        • 招聘中
        • Research Site
      • Xuzhou、中国、221009
        • 招聘中
        • Research Site
      • Zhanjiang、中国、524003
        • 招聘中
        • Research Site
      • Zhengzhou、中国、450008
        • 招聘中
        • Research Site
      • Zhengzhou、中国、450052
        • 招聘中
        • Research Site
    • Ontario
      • Barrie、Ontario、加拿大、L4M 6M2
        • 招聘中
        • Research Site
      • Hamilton、Ontario、加拿大、L8V 5C2
        • 招聘中
        • Research Site
      • Toronto、Ontario、加拿大、M5G 2M9
        • 招聘中
        • Research Site
    • Quebec
      • Greenfield Park、Quebec、加拿大、J4V 2H1
        • 招聘中
        • Research Site
      • Montreal、Quebec、加拿大、H4A 3J1
        • 招聘中
        • Research Site
      • Montreal、Quebec、加拿大、H2X 0A9
        • 招聘中
        • Research Site
      • Québec、Quebec、加拿大、G1S 4L8
        • 招聘中
        • Research Site
    • Saskatchewan
      • Regina、Saskatchewan、加拿大、S4T 7T1
        • 招聘中
        • Research Site
      • Saskatoon、Saskatchewan、加拿大、S7N 4H4
        • 招聘中
        • Research Site
      • Cape Town、南非、7570
        • 招聘中
        • Research Site
      • Johannesburg、南非、2013
        • 招聘中
        • Research Site
      • Johannesburg、南非、2196
        • 招聘中
        • Research Site
      • Johannesburg、南非、2193
        • 招聘中
        • Research Site
      • Paarl、南非、7646
        • 招聘中
        • Research Site
      • Pretoria、南非、0081
        • 招聘中
        • Research Site
      • Pretoria、南非、0081
        • 完全的
        • Research Site
      • Calicut、印度、673601
        • 撤销
        • Research Site
      • Chennai、印度、600031
        • 招聘中
        • Research Site
      • Jaipur、印度、302004
        • 撤销
        • Research Site
      • Kochi、印度、682027
        • 撤销
        • Research Site
      • Kolkata、印度、700160
        • 撤销
        • Research Site
      • Kottayam、印度、686008
        • 招聘中
        • Research Site
      • Marg Jaipur、印度、302004
        • 招聘中
        • Research Site
      • Mohali、印度、160055
        • 招聘中
        • Research Site
      • Mysuru、印度、570017
        • 招聘中
        • Research Site
      • Nagpur、印度、440001
        • 招聘中
        • Research Site
      • Nashik、印度、422009
        • 招聘中
        • Research Site
      • New Delhi、印度、11029
        • 招聘中
        • Research Site
      • New Delhi、印度、110075
        • 招聘中
        • Research Site
      • Puducherry、印度、605006
        • 招聘中
        • Research Site
      • Surat、印度、395002
        • 招聘中
        • Research Site
      • Thiruvananthapuram、印度、695011
        • 招聘中
        • Research Site
      • Vadodara、印度、391760
        • 招聘中
        • Research Site
      • Visakhapatnam、印度、530053
        • 撤销
        • Research Site
      • Hsinchu、台湾、300
        • 招聘中
        • Research Site
      • Kaohsiung City、台湾、80756
        • 招聘中
        • Research Site
      • Taichung、台湾、40447
        • 招聘中
        • Research Site
      • Tainan、台湾、704
        • 招聘中
        • Research Site
      • Taipei、台湾、100
        • 招聘中
        • Research Site
      • Taipei、台湾、112
        • 招聘中
        • Research Site
      • Taipei、台湾、10449
        • 招聘中
        • Research Site
      • Taipei、台湾、11259
        • 招聘中
        • Research Site
      • Taoyuan、台湾、333
        • 招聘中
        • Research Site
      • Ankara、土耳其(türkiye)、6200
        • 招聘中
        • Research Site
      • Ankara、土耳其(türkiye)、06520
        • 招聘中
        • Research Site
      • Besevler Ankara、土耳其(türkiye)
        • 招聘中
        • Research Site
      • Istanbul、土耳其(türkiye)、34010
        • 招聘中
        • Research Site
      • Izmir、土耳其(türkiye)、35575
        • 撤销
        • Research Site
      • Küçükçekmece、土耳其(türkiye)、34295
        • 招聘中
        • Research Site
      • Samsun、土耳其(türkiye)、55200
        • 招聘中
        • Research Site
      • CD Mexico、墨西哥、04980
        • 招聘中
        • Research Site
      • Guadalajara、墨西哥、44670
        • 撤销
        • Research Site
      • Guadalajara、墨西哥、44638
        • 招聘中
        • Research Site
      • Mexico City、墨西哥、0 3100
        • 招聘中
        • Research Site
      • Mexico City、墨西哥、06760
        • 招聘中
        • Research Site
      • México、墨西哥、04700
        • 招聘中
        • Research Site
      • Tuxtla Gutiérrez、墨西哥、29090
        • 招聘中
        • Research Site
      • Barretos、巴西、14784-400
        • 招聘中
        • Research Site
      • Curitiba、巴西、80730-150
        • 招聘中
        • Research Site
      • Florianópolis、巴西、88034-000
        • 招聘中
        • Research Site
      • Goiânia、巴西、74000-000
        • 招聘中
        • Research Site
      • Itajaí、巴西、88301-220
        • 招聘中
        • Research Site
      • Porto Alegre、巴西、90035-003
        • 招聘中
        • Research Site
      • Recife、巴西、52010-075
        • 招聘中
        • Research Site
      • São Paulo、巴西、01246-000
        • 招聘中
        • Research Site
      • São Paulo、巴西、01317-001
        • 招聘中
        • Research Site
      • Teresina、巴西、64049-200
        • 招聘中
        • Research Site
      • Düsseldorf、德国、40479
        • 撤销
        • Research Site
      • Essen、德国、45136
        • 撤销
        • Research Site
      • Georgsmarienhütte、德国、49124
        • 撤销
        • Research Site
      • Hamburg、德国、20357
        • 撤销
        • Research Site
      • Hanover、德国、30625
        • 撤销
        • Research Site
      • Heidelberg、德国、69120
        • 撤销
        • Research Site
      • Heilbronn、德国、74078
        • 撤销
        • Research Site
      • Leipzig、德国、04103
        • 撤销
        • Research Site
      • Bergamo、意大利、24127
        • 招聘中
        • Research Site
      • Empoli、意大利、50053
        • 招聘中
        • Research Site
      • Milan、意大利、20132
        • 招聘中
        • Research Site
      • Milan、意大利、20141
        • 招聘中
        • Research Site
      • Modena、意大利、41124
        • 撤销
        • Research Site
      • Naples、意大利、80131
        • 招聘中
        • Research Site
      • Padova、意大利、35128
        • 招聘中
        • Research Site
      • Reggio Emilia、意大利、42123
        • 招聘中
        • Research Site
      • Roma、意大利、00168
        • 招聘中
        • Research Site
      • Rozzano、意大利、20089
        • 招聘中
        • Research Site
      • Singapore、新加坡、169610
        • 招聘中
        • Research Site
      • Singapore、新加坡、308433
        • 招聘中
        • Research Site
      • Singapore、新加坡、217562
        • 招聘中
        • Research Site
      • Singapore、新加坡、119228
        • 撤销
        • Research Site
      • Akashi-shi、日本、673-8558
        • 招聘中
        • Research Site
      • Bunkyō City、日本、113-8431
        • 招聘中
        • Research Site
      • Bunkyō City、日本、113-8677
        • 招聘中
        • Research Site
      • Chiba、日本、260-8717
        • 招聘中
        • Research Site
      • Chūōku、日本、104-0045
        • 招聘中
        • Research Site
      • Fukuoka、日本、811-1395
        • 招聘中
        • Research Site
      • Fukushima、日本、960-1295
        • 招聘中
        • Research Site
      • Gifu、日本、501-1194
        • 招聘中
        • Research Site
      • Hidaka-shi、日本、350-1298
        • 招聘中
        • Research Site
      • Hiroshima、日本、734-8551
        • 招聘中
        • Research Site
      • Hiroshima、日本、730-8518
        • 招聘中
        • Research Site
      • Isehara-shi、日本、259-1193
        • 招聘中
        • Research Site
      • Kamogawa-shi、日本、296-8602
        • 招聘中
        • Research Site
      • Kashiwa、日本、277-8577
        • 招聘中
        • Research Site
      • Kitaadachi-gun、日本、362-0806
        • 招聘中
        • Research Site
      • Kumamoto、日本、860-8556
        • 招聘中
        • Research Site
      • Kurume-shi、日本、830-0011
        • 招聘中
        • Research Site
      • Kōtoku、日本、135-8550
        • 招聘中
        • Research Site
      • Matsuyama、日本、791-0280
        • 招聘中
        • Research Site
      • Nagoya、日本、466-8560
        • 招聘中
        • Research Site
      • Nagoya、日本、467-8602
        • 招聘中
        • Research Site
      • Niigata、日本、951-8566
        • 招聘中
        • Research Site
      • Nishinomiya-shi、日本、663-8501
        • 招聘中
        • Research Site
      • Okayama、日本、700-8558
        • 招聘中
        • Research Site
      • Osaka、日本、541-8567
        • 招聘中
        • Research Site
      • Osakasayama-shi、日本、589-8511
        • 招聘中
        • Research Site
      • Ota-shi、日本、373-8550
        • 招聘中
        • Research Site
      • Sapporo、日本、003-0804
        • 招聘中
        • Research Site
      • Sendai、日本、980-8574
        • 招聘中
        • Research Site
      • Shinagawa-ku、日本、142-8666
        • 招聘中
        • Research Site
      • Shinjuku-ku、日本、162-8655
        • 招聘中
        • Research Site
      • Shinjuku-ku、日本、160-0023
        • 招聘中
        • Research Site
      • Tsu、日本、514-8507
        • 招聘中
        • Research Site
      • Tsukuba、日本、305-8577
        • 招聘中
        • Research Site
      • Yokohama、日本、241-8515
        • 招聘中
        • Research Site
      • Lille、法国、59000
        • 招聘中
        • Research Site
      • Lyon、法国、69373
        • 招聘中
        • Research Site
      • Montpellier、法国、34298
        • 招聘中
        • Research Site
      • Paris、法国、75020
        • 招聘中
        • Research Site
      • Saint-Herblain、法国、44805
        • 招聘中
        • Research Site
      • Toulouse、法国、31059
        • 招聘中
        • Research Site
      • Vandœuvre-lès-Nancy、法国、54511
        • 招聘中
        • Research Site
      • Villejuif、法国、94800
        • 招聘中
        • Research Site
      • Bialystok、波兰、15-027
        • 撤销
        • Research Site
      • Bydgoszcz、波兰、85-796
        • 撤销
        • Research Site
      • Gdansk、波兰、80-952
        • 招聘中
        • Research Site
      • Gdynia、波兰、81-519
        • 撤销
        • Research Site
      • Konin、波兰、62-500
        • 撤销
        • Research Site
      • Krakow、波兰、31-501
        • 招聘中
        • Research Site
      • Krakow、波兰、31-115
        • 撤销
        • Research Site
      • Legnica、波兰、59-220
        • 撤销
        • Research Site
      • Lodz、波兰、90-302
        • 招聘中
        • Research Site
      • Lublin、波兰、20-090
        • 撤销
        • Research Site
      • Przemyśl、波兰、37-700
        • 撤销
        • Research Site
      • Warsaw、波兰、02-781
        • 招聘中
        • Research Site
      • Wroclaw、波兰、53-413
        • 撤销
        • Research Site
      • Bangkok、泰国、10210
        • 招聘中
        • Research Site
      • Bangkok、泰国、10400
        • 招聘中
        • Research Site
      • Bangkok、泰国、10330
        • 招聘中
        • Research Site
      • Bangkok、泰国、10700
        • 招聘中
        • Research Site
      • Chiang Mai、泰国、50200
        • 招聘中
        • Research Site
      • Dusit、泰国、10300
        • 招聘中
        • Research Site
      • Khon Kaen、泰国、40002
        • 招聘中
        • Research Site
      • Songkhla、泰国、90110
        • 招聘中
        • Research Site
      • Camperdown、澳大利亚、2050
        • 招聘中
        • Research Site
      • Darlinghurst、澳大利亚、2010
        • 完全的
        • Research Site
      • Heidelberg、澳大利亚、3084
        • 完全的
        • Research Site
      • Melbourne、澳大利亚、3000
        • 招聘中
        • Research Site
      • Nedlands、澳大利亚、6009
        • 招聘中
        • Research Site
      • Waratah、澳大利亚、2298
        • 撤销
        • Research Site
    • Alabama
      • Daphne、Alabama、美国、36526
        • 招聘中
        • Research Site
    • Arkansas
      • Springdale、Arkansas、美国、72762
        • 招聘中
        • Research Site
    • California
      • Duarte、California、美国、91010
        • 撤销
        • Research Site
      • Fountain Valley、California、美国、92708
        • 尚未招聘
        • Research Site
      • Glendale、California、美国、91204
        • 招聘中
        • Research Site
      • Sacramento、California、美国、95817
        • 招聘中
        • Research Site
      • Santa Rosa、California、美国、95403
        • 撤销
        • Research Site
    • Colorado
      • Aurora、Colorado、美国、80012
        • 招聘中
        • Research Site
      • Denver、Colorado、美国、80210
        • 尚未招聘
        • Research Site
    • Connecticut
      • New Haven、Connecticut、美国、06510
        • 招聘中
        • Research Site
    • Florida
      • Altamonte Springs、Florida、美国、32701
        • 尚未招聘
        • Research Site
      • Jacksonville、Florida、美国、32256
        • 撤销
        • Research Site
      • Miami、Florida、美国、33176
        • 招聘中
        • Research Site
      • Palm Bay、Florida、美国、32909
        • 撤销
        • Research Site
      • Plantation、Florida、美国、33324
        • 招聘中
        • Research Site
    • Georgia
      • Atlanta、Georgia、美国、30318
        • 暂停
        • Research Site
    • Hawaii
      • Honolulu、Hawaii、美国、96819
        • 撤销
        • Research Site
    • Illinois
      • Chicago、Illinois、美国、60637
        • 招聘中
        • Research Site
      • Decatur、Illinois、美国、62526
        • 撤销
        • Research Site
      • Elmhurst、Illinois、美国、60126
        • 撤销
        • Research Site
      • Naperville、Illinois、美国、60540
        • 撤销
        • Research Site
    • Indiana
      • New Albany、Indiana、美国、47150
        • 撤销
        • Research Site
    • Iowa
      • Des Moines、Iowa、美国、50309
        • 招聘中
        • Research Site
    • Kentucky
      • Lexington、Kentucky、美国、40503
        • 撤销
        • Research Site
      • Louisville、Kentucky、美国、40202
        • 撤销
        • Research Site
      • Louisville、Kentucky、美国、40207
        • 撤销
        • Research Site
    • Louisiana
      • Baton Rouge、Louisiana、美国、70809
        • 招聘中
        • Research Site
      • Baton Rouge、Louisiana、美国、70808
        • 撤销
        • Research Site
    • Maryland
      • Baltimore、Maryland、美国、21215
        • 撤销
        • Research Site
      • Columbia、Maryland、美国、21044
        • 招聘中
        • Research Site
    • Massachusetts
      • Boston、Massachusetts、美国、02111
        • 撤销
        • Research Site
      • Worcester、Massachusetts、美国、01655
        • 撤销
        • Research Site
    • Michigan
      • Detroit、Michigan、美国、48201
        • 招聘中
        • Research Site
      • Grand Rapids、Michigan、美国、49503
        • 撤销
        • Research Site
    • Minnesota
      • Saint Paul、Minnesota、美国、55109
        • 招聘中
        • Research Site
    • Mississippi
      • Hattiesburg、Mississippi、美国、39401
        • 撤销
        • Research Site
    • Missouri
      • St Louis、Missouri、美国、63129
        • 招聘中
        • Research Site
    • New Mexico
      • Albuquerque、New Mexico、美国、87109
        • 招聘中
        • Research Site
    • New York
      • Albany、New York、美国、12206
        • 撤销
        • Research Site
      • New York、New York、美国、10065
        • 招聘中
        • Research Site
      • Stony Brook、New York、美国、11794-7263
        • 招聘中
        • Research Site
    • Ohio
      • Cincinnati、Ohio、美国、45219
        • 招聘中
        • Research Site
      • Cincinnati、Ohio、美国、45245
        • 招聘中
        • Research Site
      • Cleveland、Ohio、美国、44195
        • 招聘中
        • Research Site
    • Pennsylvania
      • York、Pennsylvania、美国、17403
        • 撤销
        • Research Site
    • Rhode Island
      • Providence、Rhode Island、美国、02903
        • 招聘中
        • Research Site
    • Tennessee
      • Chattanooga、Tennessee、美国、37404
        • 招聘中
        • Research Site
      • Nashville、Tennessee、美国、37203
        • 招聘中
        • Research Site
    • Texas
      • Dallas、Texas、美国、75246
        • 招聘中
        • Research Site
      • Dallas、Texas、美国、75230
        • 撤销
        • Research Site
      • Dallas、Texas、美国、75246
        • 撤销
        • Research Site
      • El Paso、Texas、美国、79902
        • 招聘中
        • Research Site
      • Flower Mound、Texas、美国、75028
        • 撤销
        • Research Site
      • Fort Worth、Texas、美国、76104
        • 撤销
        • Research Site
      • Houston、Texas、美国、77054
        • 撤销
        • Research Site
      • Houston、Texas、美国、77090
        • 撤销
        • Research Site
      • Houston、Texas、美国、77098
        • 撤销
        • Research Site
      • Kingwood、Texas、美国、77339
        • 撤销
        • Research Site
      • McKinney、Texas、美国、75071
        • 撤销
        • Research Site
      • Sugar Land、Texas、美国、77479
        • 招聘中
        • Research Site
    • Virginia
      • Charlottesville、Virginia、美国、22903
        • 招聘中
        • Research Site
      • Fairfax、Virginia、美国、22031
        • 招聘中
        • Research Site
      • Midlothian、Virginia、美国、23114
        • 招聘中
        • Research Site
      • Norfolk、Virginia、美国、23502
        • 招聘中
        • Research Site
      • Roanoke、Virginia、美国、24014
        • 招聘中
        • Research Site
    • Washington
      • Tacoma、Washington、美国、98405
        • 招聘中
        • Research Site
    • Wisconsin
      • Madison、Wisconsin、美国、53792
        • 撤销
        • Research Site
      • Cardiff、英国、CF14 2TL
        • 招聘中
        • Research Site
      • Chelsea、英国、SW3 6JJ
        • 招聘中
        • Research Site
      • Leicester、英国、Le5 4PW
        • 招聘中
        • Research Site
      • Liverpool、英国、L7 8YA
        • 终止
        • Research Site
      • London、英国、EC1A 7BE
        • 招聘中
        • Research Site
      • London、英国、SW17 0QT
        • 撤销
        • Research Site
      • Oxford、英国、OX3 7LE
        • 暂停
        • Research Site
      • Surrey、英国、GU2 7XX
        • 暂停
        • Research Site
      • Sutton、英国、SM2 5PT
        • 招聘中
        • Research Site
      • Taunton、英国、TA1 5DA
        • 招聘中
        • Research Site
      • Bacolod、菲律宾、6100
        • 招聘中
        • Research Site
      • Cebu City、菲律宾、6000
        • 招聘中
        • Research Site
      • City of Muntinlupa、菲律宾、1780
        • 招聘中
        • Research Site
      • Manila、菲律宾、1000
        • 招聘中
        • Research Site
      • Quezon City、菲律宾、1112
        • 招聘中
        • Research Site
      • San Juan City、菲律宾、1502
        • 招聘中
        • Research Site
      • Barcelona、西班牙、8035
        • 招聘中
        • Research Site
      • Barcelona、西班牙、08028
        • 撤销
        • Research Site
      • Granada、西班牙、18016
        • 招聘中
        • Research Site
      • Hospitalet deLlobregat、西班牙、08907
        • 招聘中
        • Research Site
      • Madrid、西班牙、28007
        • 招聘中
        • Research Site
      • Madrid、西班牙、28034
        • 撤销
        • Research Site
      • Pamplona、西班牙、31008
        • 招聘中
        • Research Site
      • Santander、西班牙、39008
        • 招聘中
        • Research Site
      • Da Nang、越南、550000
        • 招聘中
        • Research Site
      • Hanoi、越南、100000
        • 招聘中
        • Research Site
      • Ho Chi Minh City、越南、700000
        • 招聘中
        • Research Site
      • Huế、越南、530000
        • 招聘中
        • Research Site
      • Hồ Chí Minh、越南、700000
        • 招聘中
        • Research Site
      • Viet Tri、越南、35000
        • 招聘中
        • Research Site
      • Vinh、越南、460000
        • 招聘中
        • Research Site
      • CABA、阿根廷、1425
        • 招聘中
        • Research Site
      • CABA、阿根廷、1414
        • 招聘中
        • Research Site
      • CABA、阿根廷、C1425
        • 撤销
        • Research Site
      • CABA、阿根廷、C1113AAE
        • 招聘中
        • Research Site
      • Ciudad Autónoma Buenos Aires、阿根廷、C1430EFA
        • 招聘中
        • Research Site
      • Ciudad de Buenos Aires、阿根廷、C1015ABO
        • 招聘中
        • Research Site
      • Rosario、阿根廷、2000
        • 招聘中
        • Research Site
      • San Nicolás de los Arroyos、阿根廷、B2900
        • 撤销
        • Research Site
      • Busan、韩国、49241
        • 完全的
        • Research Site
      • Daegu、韩国、41404
        • 招聘中
        • Research Site
      • Goyang-si、韩国、10408
        • 招聘中
        • Research Site
      • Seongnam-si、韩国、13620
        • 招聘中
        • Research Site
      • Seoul、韩国、03080
        • 招聘中
        • Research Site
      • Seoul、韩国、06351
        • 招聘中
        • Research Site
      • Seoul、韩国、05505
        • 招聘中
        • Research Site
      • Seoul、韩国、03722
        • 招聘中
        • Research Site
      • Seoul、韩国、06591
        • 招聘中
        • Research Site
      • Seoul、韩国、02841
        • 招聘中
        • Research Site
      • Seoul、韩国、06273
        • 招聘中
        • Research Site
      • Hong Kong、香港、999077
        • 招聘中
        • Research Site

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Key Inclusion Criteria

  • Histologically or cytologically documented locally recurrent inoperable, which cannot be treated with curative intent, or metastatic TNBC, as defined by the ASCO-CAP guidelines.

  • ECOG PS 0 or 1.

  • Participants are expected to provide an FFPE tumour sample collected from a locally recurrent inoperable or metastatic tumour. Alternatively, an archival FFPE tumour sample can be submitted; it must have been collected ≤ 3 years prior to the participant signing informed consent (screening start).

  • PD-L1 positive TNBC based on results from an appropriately validated investigational PD-L1 (22C3) assay (CPS ≥ 10) from a sponsor designated central laboratory.

  • No prior chemotherapy or other systemic anti-cancer therapy for metastatic or locally recurrent inoperable breast cancer.

    - Patients with recurrent disease will be eligible if they have completed treatment for Stage I-III breast cancer, if indicated, and ≥6 months have elapsed between completion of treatment with curative intent and the first documented recurrence.

  • Eligible for one of the chemotherapy options listed as ICC (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin).

  • Measurable disease as per RECIST 1.1.

  • Adequate bone marrow reserve and organ function.

  • Male and female participants of childbearing potential must agree to use protocol-specified method(s) of contraception.

Key Exclusion Criteria

  • As judged by investigator, any evidence of diseases (such as severe or uncontrolled medical conditions including systemic diseases, uncontrolled hypertension, serious gastrointestinal conditions associated with diarrhoea, chronic diverticulitis or previous complicated diverticulitis, history of allogeneic organ transplant, and active bleeding diseases, ongoing and active infection, significant cardiac conditions, substance abuse, psychiatric illness/social situation or psychological conditions) which, in the investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.

  • History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 2 years before Cycle 1 Day 1 and of low potential risk for recurrence.

  • Participants with a history of previously treated neoplastic spinal cord compression or treated, clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.

    - Participants with treated clinically inactive brain metastases that are no longer symptomatic, who require no treatment with corticosteroids or anticonvulsants, may be included in the study if they have recovered from acute toxic effects of radiotherapy.

  • Uncontrolled infection requiring IV antibiotics, antivirals or antifungals.

  • Active or uncontrolled hepatitis B or C virus infection.

  • Known HIV infection that is not well controlled.

  • Uncontrolled or significant cardiac disease.

  • History of non-infectious ILD/pneumonitis (including radiation pneumonitis) that required steroids, current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.

  • Clinically severe pulmonary function compromise.

  • Clinically significant corneal disease.

  • Active or prior documented autoimmune or inflammatory disorders.

  • Prior exposure to any treatment including ADC containing a chemotherapeutic agent targeting topoisomerase I and TROP2-targeted therapy.

  • Any concurrent anti-cancer treatment.

  • Participants with a known severe hypersensitivity to PD-1/PD-L1 inhibitors or Dato-DXd.

  • Currently pregnant (confirmed with positive pregnancy test), breastfeeding or planning to become pregnant.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Dato-DXd + durvalumab

Arm 1: Dato-DXd + durvalumab

Provided in 100mg vials. IV infusion. Experimental drug.

其他名称:
  • Datopotamab deruxtecan (Dato-DXd, DS-1062a)

Provided in 500mg vials. IV infusion. Experimental drug.

其他名称:
  • MEDI4736
有源比较器:Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab

Arm 2: Investigator's Choice of Chemotherapy (ICC) in combination with pembrolizumab (paclitaxel, nab-paclitaxel, or gemcitabine + carboplatin)

IV infusion. Active comparator.

IV infusion. Active comparator.

IV infusion. Active comparator.

IV infusion. Active comparator.

IV infusion. Active comparator.

实验性的:Dato-DXd

Arm 3: Dato-DXd

Provided in 100mg vials. IV infusion. Experimental drug.

其他名称:
  • Datopotamab deruxtecan (Dato-DXd, DS-1062a)

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Progression Free Survival (PFS)
大体时间:From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).

PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause. The comparison will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anticancer therapy or clinically progresses prior to RECIST 1.1 progression.

However, if the participant progresses or dies immediately after 2 or more consecutive missed visits, the participant will be censored at the time of the latest evaluable assessment prior to the 2 missed visits.

The measure of interest is the HR of PFS.

From randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause (anticipated to be up to 33 months).

次要结果测量

结果测量
措施说明
大体时间
Overall Survival (OS)
大体时间:From randomisation until the date of death due to any cause (anticipated to be up to 64 months).

OS is defined as the time from randomisation until the date of death due to any cause.

From randomisation until the date of death due to any cause (anticipated to be up to 64 months).
Objective Response Rate (ORR)
大体时间:From randomisation up until progression (anticipated to be up to 33 months).

ORR is defined as the proportion of participants who have a CR or PR, as determined by the BICR/investigator assessment, per RECIST 1.1.

From randomisation up until progression (anticipated to be up to 33 months).
Duration of Response (DoR)
大体时间:From the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 33 months).

DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause.

From the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR/investigator assessment or death due to any cause (anticipated to be up to 33 months).
Progression-Free Survival (PFS) by Investigator assessment
大体时间:From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 33 months).

PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by investigator, or death due to any cause.

From randomisation until progression per RECIST 1.1 as assessed by the investigator, or death due to any cause (anticipated to be up to 33 months).
Clinical Benefit Rate (CBR) at 24 weeks
大体时间:From randomisation up until progression, or the last evaluable assessment in the absence of progression (anticipated to be up to 33 months).

CBR at 24 weeks is defined as the percentage of participants who have a CR or PR or who have SD, per RECIST 1.1, as assessed by BICR/per investigator assessment and derived from the raw tumour data for at least 23 weeks after randomisation.

From randomisation up until progression, or the last evaluable assessment in the absence of progression (anticipated to be up to 33 months).
Time to deterioration (TTD) in breast and arm symptoms in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
大体时间:From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).

TTD in breast symptoms and arm symptoms as measured by the arm symptoms scale from EORTC IL116 TTD is defined as time from the date of randomisation to the date of deterioration.

Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold.

From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
Time to deterioration (TTD) in pain in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
大体时间:Time from the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).

TTD in pain as measured by the EORTC IL199.

Time from the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
Time to deterioration (TTD) in physical functioning in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
大体时间:From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).

TTD in physical function as measured by the PROMIS Short Form v2.0 - Physical Function 8c.

From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
Time to deterioration (TTD) in GHS/QoL in participants treated with Dato-DXd + durvalumab compared with ICC + pembrolizumab
大体时间:From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).

TTD in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172.

From the date of randomisation to the date of deterioration (from randomization to 18 weeks post-progression).
Time to First Subsequent Therapy (TFST)
大体时间:From randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 64 months).

TFST is defined as the time from randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause.

From randomisation until the start date of the first subsequent anticancer therapy after discontinuation of randomised treatment, or death due to any cause (anticipated to be up to 64 months).
Time to Second Subsequent Therapy (TSST)
大体时间:From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 64 months).

TSST is defined as the time from randomisation until the start date of the second subsequent anticancer therapy after discontinuation of first subsequent treatment, or death due to any cause.

From randomisation until the start date of the second subsequent anti cancer therapy after discontinuation of first subsequent treatment, or death due to any cause (anticipated to be up to 64 months).
Progression Free Survival 2 (PFS2)
大体时间:From the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 64 months).

PFS2 will be defined as the time from the randomisation to the earliest progression event (following the initial progression), subsequent to first subsequent therapy, or death. The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard clinical practice based on radiological or clinical progression.

From the randomisation to the earliest of the progression event (following the initial progression), subsequent to first subsequent therapy, or death (anticipated to be up to 64 months).
Pharmacokinetics of Dato-DXd in combination with durvalumab
大体时间:From first dose to end of treatment (anticipated to be up to 33 months).

Concentration of Dato-DXd, total anti-TROP2 antibody, and DXd (payload) in plasma.

From first dose to end of treatment (anticipated to be up to 33 months).
Immunogenicity of Dato-DXd in combination with durvalumab
大体时间:From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).

Presence of antidrug antibodies for Dato-DXd (confirmatory results: positive or negative, titres).

From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).
Safety and tolerability of Dato-DXd + durvalumab as compared with ICC + pembrolizumab
大体时间:From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).

Safety and tolerability will be evaluated in the safety population in terms of AEs.

From first dose to end of treatment safety follow-up (anticipated to be up to 33 months).

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

赞助

合作者

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2023年11月23日

初级完成 (估计的)

2027年7月28日

研究完成 (估计的)

2030年9月30日

研究注册日期

首次提交

2023年10月23日

首先提交符合 QC 标准的

2023年10月23日

首次发布 (实际的)

2023年10月27日

研究记录更新

最后更新发布 (实际的)

2026年9月25日

上次提交的符合 QC 标准的更新

2026年9月24日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

是的

IPD 计划说明

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

"Yes", indicates that AZ are accepting requests for IPD, but this does not mean all requests will be approved.

IPD 共享时间框架

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD 共享访问标准

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD 共享支持信息类型

  • 研究方案
  • 树液

药物和器械信息、研究文件

研究美国 FDA 监管的药品

是的

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅